Skip to main content
. Author manuscript; available in PMC: 2009 Sep 29.
Published in final edited form as: Am J Psychiatry. 2005 Jun;162(6):1090–1099. doi: 10.1176/appi.ajp.162.6.1090

TABLE 3.

Prepulse Inhibition in Children With 22q11 Deletion Syndrome and Sibling Comparison Subjects, Based on Eye Blinks Following Startling Auditory Pulses Presented Alone and After Prepulses

Test Value
Normality of Distribution
Group and Test Variable Mean SD Minimum Maximum Kolmogorov-Smirnov χ2 p
Children with 22q11 deletion syndrome (N=25)
 Maximum amplitude of peak (mV)
  Pulse trials 3170.35 1435.42 1175.64 5834.31 0.30 0.99
  Prepulse trials 2452.14 1532.03 168.94 5739.10 0.67 0.99
 Time of peak (msec)a
  Pulse trials 101.44 95.16 88.74 139.62 1.85 0.79
  Prepulse trials 104.23 95.31 84.95 141.02 1.19 0.99
 Difference in latency (time of peak in pulse trials minus time
  of peak in prepulse trials)
0.22 14.71 −25.00 51.75 0.72 0.99
 Difference in maximum amplitude of peak (maximum in
  pulse trials minus maximum in prepulse trials)
718.21 905.88 −1055.94 2724.37 1.19 0.99
 Percentage prepulse inhibitionb 26.06 29.15 −30.55 85.64 0.67 0.99
Sibling comparison subjects (N=23)
 Maximum amplitude of peak (mV)
  Pulse trials 2947.20 1237.38 665.85 5792.88 1.46 0.97
  Prepulse trials 1649.54 1052.19 91.19 4154.33 2.27 0.64
 Time of peak (msec)a
  Pulse trials 96.72 92.23 84.40 117.16 0.82 0.99
  Prepulse trials 94.73 85.41 66.79 124.26 1.18 0.99
 Difference in latency (time of peak in pulse trials minus time
  of peak in prepulse trials)
3.80 10.28 −10.07 30.50 2.17 0.67
 Difference in maximum amplitude of peak (maximum in
  pulse trials minus maximum in prepulse trials)
1297.66 862.17 −172.17 2911.81 0.36 0.99
 Percentage prepulse inhibitionb 46.41 25.60 −5.34 92.52 1.04 0.99
a

Exponentiated log values; lower standard deviation values are given. For children with the deletion syndrome, upper SD=119.43 for pulse trials and upper SD=118.10 for prepulse trials. For sibling comparison subjects, upper SD=102.84 for pulse trials and upper SD=107.92 for prepulse trials.

b

Calculated as 100 − ([peak in prepulse trials/peak in pulse trials] × 100).

HHS Vulnerability Disclosure